In 2014, eight new medicines for cancer were recommended for marketing authorisation by the European Medicines Agency (EMA), of which four target rare cancers.
In particular, the EMA recommended approval of vintafolide in ovarian cancer, trametinib in melanoma, obinituzumab in chronic lymphocytic leukaemia (CLL), ibrutinib for mantle cell lymphoma and CLL, idelalisib for CLL and follicular lymphoma, nintedanib for non-small cell lung cancer (NSCLC), ramucirumab in gastric cancer and cancer of gastro-oesophageal junction, and olaparib for ovarian cancer.
In addition, the EMA approved biosimilar filgrastim for the management of febrile neutropenia in patients treated with cytotoxic chemotherapy. Read more here.
No comments:
Post a Comment